Nick Scott-Ram, MA, PhD, MBE
Nick has over 22 years experience in commercial and business development in the life sciences sector. He specialises in strategy development, business development, intellectual property and the commercialisation of technologies and products.
Nick has an honours degree in Natural Sciences and a PhD in Philosophy of Science from Cambridge University. After raising over £1 million for a small start-up vaccine company, he joined British Biotech in 1989 where he was involved in a variety of positions covering research management, business development and corporate development. In 1997 he joined Quercus Management as a consultant, working with a broad range of clients including Avidex, Oxford BioMedica, and the MRC. In 2002 was appointed Vice President, Corporate Affairs at Powderject Pharmaceuticals plc where his responsibilities included corporate strategy and government affairs. After the acquisition of PowderJect by Chiron, he went back into consultancy, working for a range of clients including SMEs, the NERC, the Oxford Biomedical Research Centre, the Department of Health (DH) and the National Cancer Action Team. He has also worked with Drayson Motor Racing in the area of electric car technology. He has assisted the DH on a number of projects involved in due diligence assessment, and the commercialisation and licensing of products. From 2006 he has also worked as special industry consultant to the BioIndustry Association in a variety of areas, including the Pharmaceutical Price Regulation Scheme, Value-Based Pricing, NICE and the 2009 Office for Life Sciences Blueprint on spin-outs, innovation and delivery. He has been a member of a number of ABPI Committees relating to pricing and uptake. In 2010 he joined Blue Sky Corporate Solutions.
Nick was heavily involved in framing and delivering the biotech industry’s response on the Biotechnology Patents Directive through the European legislative process, chairing a variety of industry groups including the BIA’s Intellectual Property Advisory Committee, ABPI's Patents Task Force, and in Europe Europabio's Task Force on Patents and FEBC’s Patents Policy Group. He was awarded an MBE for services to Biotechnology in 2001. He has been editor of the Journal of Commercial Biotechnology and on the Editorial Board of Bioscience Law Review.